Patrys Ltd

  • IPO date: 2007-07-20
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Company website

Company description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Financial highlights

Market Capitalization$14.4021 million
P/E Ratio0
P/E Growth Ratio
Book Value0.003
Dividend Per Share0
Earnings Per Share-0.0034
EBITDA-7,014.637
Profit Margin-2.4761
Operating Margin TTM-2.4761
Return on Assets TTM-0.4107
Return on Equity TTM-69.6938
Revenue TTM2,851.908

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
2007-06-30 60
2008-06-30 1,112 8,669.798
2009-06-30 3.735 3.735 11,904.185
2010-06-30 4.654 4.654 10,125.258
2011-06-30 7.599 7.599 9,260.167
2012-06-30 4.851 4.851 7,953.28
2013-06-30 2.643 2.643 5,345.383
2014-06-30 760 0 759.683 8,585.412
2015-06-30 952.15 0 2,224.481 6,311.706
2016-06-30 864.81 0 867.653 2,017.15
2017-06-30 531.73 0 531.729 2,460.761
2018-06-30 27.5 0 27.5 3,065.61
2019-06-30 27.5 27.5 4,304.002
2020-06-30 27.5 27.5 3,569.169
2021-06-30 27.5 27.5 5,449.861
2022-06-30 27.5 27.5 10,161.489
2023-06-30 2,851.91 9,960.519

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
2007-06-30 753.003 818.81 2,356 8,334.74
2008-06-30 15,233.976 23,857.975 882.3 9.158 25 31,580.827
2009-06-30 9,595.669 19,177.243 1,459.667 24.93 34,677.027
2010-06-30 6,810.098 16,306.876 1,074.11 4.217 15 39,634.53
2011-06-30 6,203.135 14,846.227 1,380.74 45,075.202
2012-06-30 6,189.11 13,362.175 916.357 49,136.175
2013-06-30 5,232.298 11,853.845 1,081.243 50,712.575
2014-06-30 8,643.507 14,813.698 2,379.429 59,675.971
2015-06-30 4,646.527 4,772.623 802.283 59,675.971
2016-06-30 3,215.039 4,258.728 620.259 60,035.971
2017-06-30 1,910.952 3,158.631 495.534 0 60,035.971
2018-06-30 4,605.459 7,973.247 681.772 0 67,039.044
2019-06-30 6,473.84 7,933.878 637.424 0 67,066.992
2020-06-30 3,981.21 5,376.425 498.384 0 67,086.513
2021-06-30 6,916.604 12,892.024 849.864 0 78,112.036
2022-06-30 7,817.841 13,969.977 542.825 0 85,723.696
2023-06-30 3,045.516 7,524.476 686.898 0 85,730.143

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
2007-06-30 2,321.607
2008-06-30 -7,323.602 12,912.369 2,321.607 15,233.976
2009-06-30 -8,662.339 -5,638.307 15,233.976 9,595.669
2010-06-30 -7,535.123 -2,812.436 9,595.669 6,783.233
2011-06-30 -7,421.67 -580.098 6,783.233 6,203.135
2012-06-30 -5,108.891 -14.025 6,203.135 6,189.11
2013-06-30 -3,529.095 -956.812 6,189.11 5,232.298
2014-06-30 -7,289.09 -5,089.233 3,411.209 5,232.298 8,643.507
2015-06-30 -8,470.382 -4,114.78 -3,996.98 8,643.507 4,646.527
2016-06-30 -1,080.784 -1,531.36 -1,431.488 4,646.527 3,215.039
2017-06-30 -1,057.876 -1,276.981 -1,304.087 3,215.039 1,910.952
2018-06-30 -2,497.252 -2,086.722 2,694.507 1,910.952 4,605.459
2019-06-30 3,453.85 -129.185 1,868.381 4,605.459 6,473.84
2020-06-30 -1,955.409 -2,495.525 -2,492.63 6,473.84 3,981.21
2021-06-30 -2,703.479 -3,877.157 2,935.394 3,981.21 6,916.604
2022-06-30 -6,788.459 -6,740.909 901.237 6,916.604 7,817.841
2023-06-30 -7,061.624 -5,778.822 -4,772.325 7,817.841 3,045.516